FDA
-
-
-
-
-
-
-
TG Therapeutics starts Phase 2 trial of Briumvi for schizophrenia
-
-
-
-
-
-
-
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
-
-
-
-
-
-
-
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
-
-
-
-
-
-
-
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
-
-
-
-
-
-
-
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
-
-
-
-
-
-
-
TG Therapeutics to present BRIUMVI data at multiple sclerosis conference
-
-
-
-
-
-
-
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
-
330,707 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

